aTyr Pharma, Inc. Forecast, price target & analysts
aTyr Pharma, Inc. Target price 2025 - Analyst rating & recommendation
aTyr Pharma, Inc. Classifications & Recommendation:
aTyr Pharma, Inc. Price Target
| Target Price | $18.55 |
| Price | $2.96 |
| Potential |
526.69%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target aTyr Pharma, Inc. 2026 .
The average aTyr Pharma, Inc. target price is $18.55.
This is
526.69%
register free of charge
$35.00
1,082.43%
register free of charge
$9.00
204.05%
register free of charge
|
|
| A rating was issued by 11 analysts: 11 Analysts recommend aTyr Pharma, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the aTyr Pharma, Inc. stock has an average upside potential 2026 of
526.69%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.24 | 2.02 |
| 31.43% | 743.13% | |
| EBITDA Margin | -27,654.17% | -3,647.06% |
| 85.49% | 86.81% | |
| Net Margin | -30,114.33% | -3,040.07% |
| 33.42% | 89.90% |
11 Analysts have issued a sales forecast aTyr Pharma, Inc. 2025 . The average aTyr Pharma, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an aTyr Pharma, Inc. EBITDA forecast 2025. The average aTyr Pharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 aTyr Pharma, Inc. Analysts have issued a net profit forecast 2025. The average aTyr Pharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.86 | -0.73 |
| 8.51% | 15.12% | |
| P/E | negative | |
| EV/Sales | 100.80 |
5 Analysts have issued a aTyr Pharma, Inc. forecast for earnings per share. The average aTyr Pharma, Inc. EPS is
This results in the following potential growth metrics and future valuations:
aTyr Pharma, Inc....
Current aTyr Pharma, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 03 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 29 2024 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 03 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 29 2024 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
